<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984902</url>
  </required_header>
  <id_info>
    <org_study_id>CP026</org_study_id>
    <nct_id>NCT04984902</nct_id>
  </id_info>
  <brief_title>Reduction of BK Viremia in Kidney Transplant Patients</brief_title>
  <acronym>CP026</acronym>
  <official_title>Reduction of BK Viremia in Kidney Transplant Patients Using the Seraph 100 Microbind® Affinity (Seraph 100) Blood Filter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ExThera Medical Europe BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ExThera Medical Europe BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reduction of BK Viremia by treating kidney transplant patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      a clinical investigation plan (CIP) for the &quot;Reduction of BK viremia in kidney transplant&#xD;
      patients using the Seraph 100 Microbind® Affinity (Seraph 100) Blood Filter&quot; clinical study,&#xD;
      where BK is an abbreviation of the name of the first patient whom the virus was isolated from&#xD;
      in 1971. This clinical study is intended to evaluate the reduction of BK viremia by treating&#xD;
      kidney transplant patients with the Seraph 100 Microbind® Affinity Blood Filter from ExThera&#xD;
      Medical. This clinical study is sponsored by ExThera Medical Corporation.&#xD;
&#xD;
      This clinical study will be conducted in accordance with this CIP. All parties involved in&#xD;
      the conduct of the clinical study will be qualified by education, training, or experience to&#xD;
      perform their tasks and this training will be documented appropriately.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The primary objective is to demonstrate the reduction of BK viremia by treating kidney transplant patients with the Seraph 100 Microbind® Affinity Blood Filter from ExThera Medical.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in log 10 viral load</measure>
    <time_frame>At day 0 and the following 3 treatments within five days after beginning with the first treatment.</time_frame>
    <description>Time-weighted change from baseline in log10 viral load within five days after first treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with leukopenia</measure>
    <time_frame>At day 0 and the following 3 treatments within five days after beginning with the first treatment.</time_frame>
    <description>Number of participants with leukopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with increase in serum creatinine</measure>
    <time_frame>At day 0 and the following 3 treatments within five days after beginning with the first treatment.</time_frame>
    <description>Number of participants with increase in serum creatinine between the treatment days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with inoperative hypotension</measure>
    <time_frame>At 0 and the following 3 treatments within five days after beginning with the first treatment.</time_frame>
    <description>Number of participants with inoperative hypotension per treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with decreasing haemoglobin measurements</measure>
    <time_frame>At day 0 and the following 3 treatments within five days after beginning with the first treatment.</time_frame>
    <description>Number of participants with decreasing haemoglobin measurements per treatment period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>N (%) of patients with treatment emergent adverse events</measure>
    <time_frame>2 months</time_frame>
    <description>N (%) of patients with treatment emergent adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory data</measure>
    <time_frame>2 months</time_frame>
    <description>Laboratory data (Blood test, Hematology, chemistry and coagulation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital signs score</measure>
    <time_frame>2 months</time_frame>
    <description>Vital signs score</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical examination score</measure>
    <time_frame>2 months</time_frame>
    <description>Physical examination score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Kidney Transplant Infection</condition>
  <condition>Kidney Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Microbind® Affinity Blood Filter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extracorporal therapy</intervention_name>
    <description>Extracorporal therapy</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Kidney transplant patients with a BK-viraemia ≥ 10,000 IU/ml.&#xD;
&#xD;
          2. Be ≥ 18 years old and ≤ 90 years old&#xD;
&#xD;
          3. Existing hemodialysis access&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is currently participating in another clinical investigation&#xD;
&#xD;
          2. Pregnant or nursing subjects and those who plan pregnancy during the clinical&#xD;
             investigation follow-up period&#xD;
&#xD;
          3. Presence of comorbid conditions, or other medical, social, or psychological conditions&#xD;
             that, in the investigator's opinion, could limit the subject's ability to participate&#xD;
             in the clinical investigation or to comply with follow-up requirements, or impact the&#xD;
             scientific soundness of the clinical investigation results&#xD;
&#xD;
          4. Have Child-Pugh Class C cirrhosis&#xD;
&#xD;
          5. Have platelet count &lt;30.000/uL&#xD;
&#xD;
          6. Contraindications for heparin sodium for injection&#xD;
&#xD;
          7. Subjects demonstrating any contraindication for this treatment as described in the IFU&#xD;
&#xD;
          8. Patients without existing hemodialysis access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bartosz Tyczynski, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carla Kikken-Jussen</last_name>
    <phone>+31 43 8200 399</phone>
    <email>carla@extheramedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Bartosz Tyczynski, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Kristina Boss, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Bartosz Tyczynski, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Boss, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BK Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

